Clinical data | |
---|---|
Trade names | Depixol, Fluanxol |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
Pregnancy category |
|
Routes of administration | Oral, IM (including a depot) |
Drug class | Typical antipsychotic |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 40–55% (oral)[2] |
Metabolism | Gut wall, hepatic[4] |
Elimination half-life | 35 hours[2] |
Excretion | Renal (negligible)[3] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.018.459 |
Chemical and physical data | |
Formula | C23H25F3N2OS |
Molar mass | 434.52 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Flupentixol (INN), also known as flupenthixol (former BAN), marketed under brand names such as Depixol and Fluanxol is a typical antipsychotic drug of the thioxanthene class. It was introduced in 1965 by Lundbeck. In addition to single drug preparations, it is also available as flupentixol/melitracen—a combination product containing both melitracen (a tricyclic antidepressant) and flupentixol (marketed as Deanxit). Flupentixol is not approved for use in the United States. It is, however, approved for use in the UK,[5] Australia,[6] Canada, Russian Federation,[7] South Africa, New Zealand, Philippines, Iran, Germany, and various other countries.